drugset
drugset / Trial / NCT04883593

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593 ↗

Phase 0 Completed 160 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.

Timeline

Start
2020-09-03
Primary completion
2021-02-20
Completion
2021-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject TA103 Unknown — Topical

Indications

tinea pedis